Science Explorer Interactive view Map
Company · Seongnam-si · South Korea

Corepharmbio (South Korea)

corepharm.comROR OpenAlex
Research works
1
fractional, all time
Citations
1
0.9 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
29%
world 28%

Not ranked overall: Corepharmbio (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does Corepharmbio (South Korea) publish most on?

By volume in 2022–2025: PARP inhibition in cancer therapy, DNA Repair Mechanisms, Sirtuins and Resveratrol in Medicine and Signaling Pathways in Disease.

PARP inhibition in cance…0PARP inhibition in cancer therapy: 0 fractional worksDNA Repair Mechanisms0DNA Repair Mechanisms: 0 fractional worksSirtuins and Resveratrol…0Sirtuins and Resveratrol in Medicine: 0 fractional worksSignaling Pathways in Di…0Signaling Pathways in Disease: 0 fractional works
OncologyMolecular BiologyGeriatrics and Gerontology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 PARP inhibition in cancer therapy Oncology 0 works
  2. 2 DNA Repair Mechanisms Molecular Biology 0 works
  3. 3 Sirtuins and Resveratrol in Medicine Geriatrics and Gerontology 0 works
  4. 4 Signaling Pathways in Disease Molecular Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available28.6%not open71.4%

World: 28% of research is openly available.

with international co-authors28.6%domestic only71.4%

World: 19% is written across borders.

Other research institutions in Seongnam-si

All research institutions in Seongnam-si

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.